论文部分内容阅读
46例早期糖尿病肾病患者随机分为对照组与厄贝沙坦治疗组各23例,在将血压及血糖控制稳定的情况下,进行治疗前后对比性分析。结果:两组病人经过治疗12周后,通过观察指标分析厄贝沙坦组的24h尿蛋白排泄率、血清hs-CRP水平均明显降低(P<0.05)。结论:厄贝沙坦确有血压非依赖性降尿蛋白效应,此效应与其阻断AⅡ作用外,还与其具有阻止血管重塑和血管内皮炎症细胞的粘附作用有关。提示厄贝沙坦在治疗早期糖尿病肾病中可延缓患者病情及肾脏损害。
Forty-six patients with early diabetic nephropathy were randomly divided into control group and irbesartan-treated group, with 23 cases in each group. Before and after treatment, blood pressure and blood glucose control were stable. Results: After 12 weeks of treatment, the urinary protein excretion rate and serum hs-CRP level of irbesartan group were significantly decreased by observing the index (P <0.05). CONCLUSION: Irbesartan does have a blood pressure-independent proteinuria effect, which is related to its effect of blocking AII and preventing its adhesion to vascular remodeling and endothelium-derived inflammatory cells. Tip irbesartan in the treatment of early diabetic nephropathy can delay the patient’s condition and kidney damage.